Comparison · NCT01468909-deaths
Paclitaxel + Placebo vs Paclitaxel + Pazopanib: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Paclitaxel + Placebo vs Paclitaxel + Pazopanib: deaths from any cause. Trial comparisons, record NCT01468909-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01468909-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.4 | 0.276 | 0.538 | wilson | |
| Risk in group 2 | 0.442 | 0.316 | 0.577 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0423 | -0.225 | 0.145 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.904 | 0.573 | 1.43 | log | |
| Odds ratio, group 1 over group 2 | 0.841 | 0.383 | 1.85 | log | |
| Number needed to treat, for one fewer death from any cause on Paclitaxel + Placebo than on Paclitaxel + Pazopanib | 23.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Paclitaxel + Placebo | Paclitaxel 80 mg/m2 administered weekly on days 1, 8 and 15 with Placebo PO daily | 20 | 50 | EG000 |
| Group 2 | Paclitaxel + Pazopanib | Paclitaxel 80 mg/m2 administered weekly on days 1, 8 and 15 with Pazopanib 800 mg PO daily | 23 | 52 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Every 28 days (1cycle) while on study treatment. Up to 30 days after treatment ends, up to 5 years.
Source ClinicalTrials.gov
Trial
- Title
- Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
- NCT number
- NCT01468909
- Phases
- PHASE2
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Paclitaxel, Pazopanib Hydrochloride, Placebo
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2019-04-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01468909?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01468909-deaths